162 related articles for article (PubMed ID: 25037069)
1. Biosimilar drugs, myths and reality.
Hernández-García C
Reumatol Clin; 2014; 10(6):351-2. PubMed ID: 25037069
[No Abstract] [Full Text] [Related]
2. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
Müller-Ladner U; Hong S; Oh C; Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis.
Mengato D; Messori A
Clin Exp Rheumatol; 2018; 36(6):1118. PubMed ID: 29600941
[No Abstract] [Full Text] [Related]
4. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
Zhao S; Chadwick L; Mysler E; Moots RJ
Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742
[TBL] [Abstract][Full Text] [Related]
5. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
Braun J; Kay J
Expert Opin Drug Saf; 2017 Mar; 16(3):289-302. PubMed ID: 28068848
[TBL] [Abstract][Full Text] [Related]
6. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars for the management of rheumatoid arthritis: economic considerations.
Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
[TBL] [Abstract][Full Text] [Related]
8. Position paper of Italian rheumatologists on the use of biosimilar drugs.
Atzeni F; Sebastiani M; Ricci C; Celano A; Gremese E; Iannone F; Meroni PL; Minghetti P; Sarzi-Puttini P; Ferraccioli G; Lapadula G
Clin Exp Rheumatol; 2015; 33(1):1-4. PubMed ID: 25436597
[TBL] [Abstract][Full Text] [Related]
9. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J; Kudrin A
Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
[TBL] [Abstract][Full Text] [Related]
10. Advances in rheumatoid arthritis.
Jones G; Nash P; Hall S
Med J Aust; 2017 Mar; 206(5):221-224. PubMed ID: 28301793
[TBL] [Abstract][Full Text] [Related]
11. Subsequent entry biologics/biosimilars: a viewpoint from Canada.
Russell AS; Ahluwalla V; Barnabe C; Jamal S; Offer RC; Olszynski WP; Shojania K; Haraoui B
Clin Rheumatol; 2012 Sep; 31(9):1289-92. PubMed ID: 22923182
[TBL] [Abstract][Full Text] [Related]
12. Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto.
Pham C; Niu F; Hui RL; Le KN; Delate T
Clin Rheumatol; 2024 Mar; 43(3):1269-1270. PubMed ID: 37989973
[No Abstract] [Full Text] [Related]
13. [Implementation and use of biosimilars in the therapy of inflammatory rheumatic diseases: Statement of the German Society of Rheumatology].
Lorenz HM; Braun J; Krüger K; Schneider M
Z Rheumatol; 2014 Nov; 73(9):784-6. PubMed ID: 25373548
[No Abstract] [Full Text] [Related]
14. [Patient safety first. position paper of the German Rheumatism -- Ligazur introduction of biosimilars].
Z Rheumatol; 2014 Sep; 73(7):676. PubMed ID: 25320752
[No Abstract] [Full Text] [Related]
15. Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.
Scheinberg M; Castañeda-Hernández G
Arthritis Res Ther; 2014 Dec; 16(6):501. PubMed ID: 25677586
[TBL] [Abstract][Full Text] [Related]
16. Therapy: The NICE position on indications for biologics and biosimilars.
Scheinberg M; Gomez-Reino JJ
Nat Rev Rheumatol; 2016 May; 12(5):255-6. PubMed ID: 27080695
[No Abstract] [Full Text] [Related]
17. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
Yoo DH; Oh C; Hong S; Park W
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S15-24. PubMed ID: 26395833
[TBL] [Abstract][Full Text] [Related]
18. The confidence of rheumatologists about switching to biosimilars for their patients.
Goll GL; Haavardsholm EA; Kvien TK
Joint Bone Spine; 2018 Oct; 85(5):507-509. PubMed ID: 29631065
[No Abstract] [Full Text] [Related]
19. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
[TBL] [Abstract][Full Text] [Related]
20. Therapy: Facing up to biosimilar agents--the ACR position.
Scheinberg M
Nat Rev Rheumatol; 2015 Jun; 11(6):322-4. PubMed ID: 25907701
[No Abstract] [Full Text] [Related]
[Next] [New Search]
